Biphenyl-Trimeric PSMA Theranostic Platform Enables PET Imaging and Optical Detection of Prostate Cancer
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.5c01166 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Yimin Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Positron-Emission Tomography, Glutamate Carboxypeptidase II, Theranostic Nanomedicine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Natural Science Foundation of Fujian Province, National Natural Science Foundation of China, Fujian Province.
Abstract (Originalsprache)
Prostate cancer (PCa) diagnosis faces challenges with current imaging tracers in sensitivity and contrast. We developed a biphenyl-trimeric PSMA-targeted theranostic system to address these challenges. A suite of trimeric PSMA probes (PSMA-T0-T6) was synthesized using a biphenyl scaffold and variable linkers, showing exceptional PSMA affinity (Ki = 0.11-0.60 nM). Preclinical studies demonstrated that [68Ga]Ga-PSMA-T3 provided superior tumor uptake (SUVmax 1.16 vs 0.61) and tumor-to-background ratios (TBR 26.82 vs 19.89) over [68Ga]Ga-PSMA-11 in 22Rv1 tumor-bearing mice. The optical counterpart, ICG-conjugated PSMA-T6, prolonged tumor retention with high tumor-to-muscle ratio (T/M = 7.3 at 24 h) and remarkable ex vivo specificity (T/M = 41.9). In first-in-human PET studies, [68Ga]Ga-PSMA-T3 showed comparable and enhanced detection rates of primary and metastatic lesions, particularly in liver and bone metastases, with higher TBR values than [68Ga]Ga-PSMA-11. Our biphenyl-trimeric PSMA platform demonstrates translational potential for enhanced diagnostic sensitivity and intraoperative management of PCa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, China.
- Department of PET/CT Diagnostic, Tianjin Medical University General Hospital, Tianjin 300052, China.
- Department of Nuclear Medicine, The First Medical Centre of Chinese PLA General Hospital, Beijing 100853, China.
- Center for Advanced Materials Research, Beijing Normal University at Zhuhai, Zhuhai 519087, China.
ORCID-Profile: Yimin Chen, Shaobo Yao, Mengchao Cui
Förderung
- Natural Science Foundation of Fujian Province
- National Natural Science Foundation of China
- Fujian Province
Zitieren
APA
Chen, Y., Yu, H., Liu, W., Wang, M., Wang, X., Zhang, X., Zhang, J., Yao, S., & Cui, M. (2025). Biphenyl-Trimeric PSMA Theranostic Platform Enables PET Imaging and Optical Detection of Prostate Cancer. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c01166
Vancouver
Chen Y, Yu H, Liu W, Wang M, Wang X, Zhang X, et al. Biphenyl-Trimeric PSMA Theranostic Platform Enables PET Imaging and Optical Detection of Prostate Cancer. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c01166
BibTeX
@article{Chen2025,
author = {Chen, Yimin and Yu, Haonan and Liu, Wanjia and Wang, Ming and Wang, Xinlin and Zhang, Xiaojun and Zhang, Jinming and Yao, Shaobo and Cui, Mengchao},
title = {Biphenyl-Trimeric PSMA Theranostic Platform Enables PET Imaging and Optical Detection of Prostate Cancer},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.5c01166}
}
EUVIMED